((RAIN)) Rainmakers-Island

[snowcloud]

MMRF NEWS --

LOS ANGELES, CA, Aug 16, 2010 (MARKETWIRE via COMTEX) -- MMRGlobal, Inc.
(OTCBB: MMRF) (jointly, "the Company" and "MMR") (www.mmrglobal.com) today filed
its quarterly statement for the six months ended June 30, 2010.

Revenues for the first six months from sales of the Company's consumer and
professional products, MyMedicalRecords, MyEsafeDepositBox and MMRPro, were up
by 58.6% over 2009. Total sales for these products, including Deferred Revenue
(the portion of the Company's sales that is to be recognized monthly over the
term of agreements with our customers), have increased by 94%. Total Revenues
for the three months ended June 30, 2010, including the Company's core products
and licensing fees, were up by 21% as compared to 2009. Total sales for the same
period, including Deferred Revenue, were up 60.7% as compared to 2009.

According to Ingrid Safranek, the Company's Chief Financial Officer, "We reduced
total liabilities by $2.4 million or 28.5%. In addition, we reduced Accounts
Payable by $451 thousand or 15%. Although we disclosed an Accounts Payable
balance of $2.5 million, $1.6 million of that balance is attributable to the
reverse merger wi th Favrille, Inc. and only $272 thousand represents MMR trade
payables necessary to operations. Accordingly, we maintain good relationships
with our vendors."

Safranek continued, "In the last quarter, we were able to issue equity in lieu
of cash to reduce liabilities by $1 million. We plan on using our equity to
further reduce liabilities and strengthen our balance sheet based on our
vendors' belief in the value of the Company. Our ability to issue equity for
services has afforded us the opportunity to support sales of MMRPro and other
advertising and marketing programs as well as continuing to exploit patent
opportunities with our biotech assets. Only $1.2 million of our loss was
cash-related. The remaining amount represents non-cash expenses driven by $5.6
million from the application of accounting principles to value derivative
liabilities and equity as well as an additional $1.0 million from stock options,
warrants and common st ock issued for services. These warrants and stock options
have enabled us to obtain services that a Company our size would not otherwise
have been able to afford."

According to Robert H. Lorsch, Chairman and CEO of MMRGlobal, "We are well on
our way toward executing on our business plan to achieve a global footprint from
which we will sell our proprietary line of Personal Health Record
(www.mmrvideos.com) and MyEsafeDepositBox (www.myesafevideos.com) products and
MMRPro professional medical record products and services (www.mmrprovideos.com).
However, growing a technology company in health care costs money. Accordingly,
we are incurring increasing costs necessary to our growth. For example, we are
now deploying development teams both in the U.S. and China to support the
UNIS-TongHe transaction."

"We are also expanding technical and development resources at home with
increased staff in support of MMRPro," said Lorsch. "This inclu des adding
resources necessary to provide services that will meet meaningful use criteria
and enable customers who use our products to qualify for government stimulus
around the world. In addition, we are relocating our most experienced
development resources to the U.S. from Nihilent headquarters in India to work
with our management team and our customers directly."

"Also, I plan on being in India in October for the launch of a Nihilent and
MMRGlobal joint sales effort to small-sized health care professionals, hospitals
and the government in India. At the same time, we are also increasing the size
of our processing, hosting and IT infrastructure, adding more feature-rich
facilities designed to reduce cost and increase scalability which should
ultimately improve margins," added Lorsch.

The Company has also begun the process of spending significantly more money on
advertising, marketing and sales promotion using television (www.mm rontv.com)
the web and through affiliate partnerships. An example is the "$25.00 Check-Up"
refund program which launched on the Company's MyMedicalRecords.com website
today.

MMR is also in the process of upgrading MMRPro (www.mmrprovideos.com), the
Company's professional document imaging and management system for health care
professionals. For instance, recently added features enable forms to be
customized to an existing office practice resulting in the ability to access
customized forms from MMRPro on demand. As such, doctors are able to use the
forms they use today and still continue to move toward meaningful use.

Additionally, the Company is working with several major hospital groups to help
market MMRPro systems to doctors associated with these specific hospital groups.
This is part of a program designed to help monetize MMRPro patient upgrades.
Also, MMR is starting to call on physician offices in the United States through< BR>the Kodak nationwide reseller channel.

Patient upgrades enable health care professionals to take advantage of the
MMRPro "Stimulus Program" (http://mmrvideos.com/stimulus). This program creates
a revenue stream for physicians from patient upgrades. The Company believes that
its Stimulus Program can generate more than twice the $44,000 in revenue for
physicians than the government's HITECH Act stimulus program in much less time.

The Company continues to actively explore opportunities with its pre-merger
Favrille biotech assets. In association with GRSworldwide, MMRGlobal is working
to bring its anti-CD20 monoclonal antibodies to market. These antibodies are
potentially useful in treating B-Cell malignancies, including Non-Hodgkin's
Lymphoma (NHL) and additional B-Cell mediated conditions such as rheumatoid
arthritis. MMR's anti-CD20 antibody asset is potentially a candidate for a next
generation of Rituximab, marketed under the t rade name Rituxan(R) in the United
States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and
under the name MabThera(R) by Roche in the rest of the world except Japan, where
it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan/MabThera is one
of the world's most successful monoclonal antibodies with reported total sales
in 2009 in excess of US$5.6 billion.

MMRGlobal also continues to pursue various national phase filings from the
Patent Cooperation Treaty patent application directed to the anti-CD20
monoclonal antibodies, including in the United States, Australia, Brazil,
Canada, China, Europe, India, Japan, South Korea and Mexico. The Company has
further been addressing opportunities pertaining to intellectual property rights
involving B and T cell vaccine technology relative to the FavID vaccine in
various stages in the United States and foreign countries through its reverse
merger with Favrille. M MRGlobal is also in the process of filing certain patents
regarding numerous aspects of the FavID vaccine, a portion of which has been
recently granted.

The Company continues its activities in support of the launch of the
Chartis-branded MyEsafeDepositBox product, which plans to provide MMR's secure
online virtual safe and Personal Health Record products and services to Chartis
policyholders worldwide, while it further works with Chartis on opportunities to
offer its products domestically as well.

Additionally, MMRGlobal is in active negotiations with one of the world's
largest financial institutions regarding the development of paperless loan
processing and delivery solutions whereby loan documents can be delivered
electronically through the Company's MyEsafeDepositBox product, with resultant
completed documents being filed in a permanent online MyEsafeDepositBox account.

"We are pursuing several Merger and Acquisition oppo rtunities that could
accelerate growth, expand the Company's product line and enable us to offer more
services consistent with criteria for meaningful use, specifically PHR and EMR
related," Lorsch added. "We have always intended to grow MMR into a much larger
organization. However, it takes money and patience to grow a company. For
example, Amazon went public in 1997, and had a net loss of $31 million, followed
by a net loss of $125 million, and almost $720 million in 1998 and 1999,
respectively. In their last annual report for the year ended 2009, they had net
income of $902 million."

About MMRGlobal, Inc. MMR Global, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit box storage
solutions, serving consumers, healthcare professionals, employers, insurance
companies, financial institutions, and profe ssional organizations and affinity
groups. MyMedicalRecords enables individuals and families to access their
medical records and other important documents, such as birth certificates,
passports, insurance policies and wills, anytime from anywhere using the
Internet. The MyMedicalRecords Personal Health Record is built on proprietary,
patented technologies to allow documents, images and voicemail messages to be
transmitted and stored in the system using a variety of methods, including fax,
phone, or file upload without relying on any specific electronic medical record
platform to populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and cost-effective
solution to digitizing paper-based medical records and sharing them with
patients in real time through an integrated patient portal. MMR is an
Independent Software Vendor Partner with Kodak to deliver an integrated turnkey
EM R solution for healthcare professionals. MMR is also an integrated service
provider on Google Health. To learn more about MMR Global, Inc. and its
products, visit www.mymedicalrecords.com and view the videos at
www.mmrtheater.com.

Forward Looking Statement Statements in this press release that are not strictly
historical in nature constitute "forward-looking statements." Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the Company's actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. Some can be identified by the use of words (and
their derivations) such as "need," "possibility," "offer," "development," "if,"
"negotiate," "when," "begun," "believe," "achieve," "will," "estimate,"
"expect," "maintain," "plan," and "continue," or the negative of these words.
Any comparisons made with other companies are for illustrative purposes only and
do not imply any similar levels of growth, revenue, or income. Factors that
could cause or contribute to such differences include, but are not limited to,
the risk the Company's products are not adopted or viewed favorably by the
health care community; risks related to the current uncertainty and instability
in financial and lending markets, including global economic uncertainties;
variations in our quarterly operating results; timing and volume of sales and
installations; length of sales cycles and the installation process; market
acceptance of new product introductions; ability to establish and maintain
strategic relationships; ability to identify and integrate acquisitions;
relationships with licensees; competitive product offerings and promotions;
changes in government laws and regulations and future changes in tax legislation
and initiatives in the health care industry; undetecte d errors in our products;
possibility of interruption at our data centers; risks related to third party
vendors; risks related to obtaining and integrating third-party licensed
technology; acceptance of the Company's marketing and promotional campaigns;
risks related to a security breach by third parties; maintaining, developing and
defending our intellectual property rights including those pertaining to our
biotechnology assets; risks associated with recruitment and retention of key
personnel; uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the Company's filings
with the Securities and Exchange Commission. Additionally, we are a developing
early-stage company and many variables can affect revenues and/or projections,
including factors out of our control. The Company is providing this information
as of the date of this release and, except as required by law, doe s not
undertake any obligation to update any forward-looking statements contained in
this release as a result of new information, future events or otherwise.





CONTACT:

Bobbie Volman

MMRGlobal, Inc.

[phone], Ext. 2005

[e-mail]



Michael Selsman

Public Communications Co.

[phone]

[e-mail]





SOURCE: MMRGlobal, Inc.




CONTACT: mailto:[e-mail]

mailto:[e-mail]




Copyright 2010 Marketwire, Inc., All rights reserved.

-0-




SUBJECT CODE: Computers and Software:Internet

; Financial Services:Commercial and Investment Banking

Financial Services:Investment Services and Trading

Financial Services:Venture Capital

Professional Services:Investor Relations

Medical and Healthcare:Facilities and Providers

Medical and Healthcare:Healthcare

Pharmaceuticals and Biotech:Equipment and Supplies

Government:National